Research articles
ScienceAsia 49 (2023):ID 786-790 |doi:
10.2306/scienceasia1513-1874.2023.072
Atractylenolide-II inhibits proliferation and migration of
glioblastoma cells
Rui Wanga,b,?, Tingting Liuc,?, Jiayu Chena,b, Dianbao Zhanga,b,*
ABSTRACT: Glioblastoma (GBM) is the most malignant and lethal brain tumor in adults, with limited therapeutic
options and dismal prognosis. Atractylenolide-II (AT-II) is a major bioactive compound from Atractylodes macrocephala
Koidz. (Baizhu in Chinese), with anti-inflammatory and anti-tumor activities. However, the anti-tumor effects of AT-II
on GBM cells remain unclear. In the present study, the cytotoxicity of AT-II on GBM cells was analyzed using CCK-8
assay, and it revealed that the cell viability was inhibited by AT-II in a dose-dependent manner. The results of Transwell
migration assay indicated that AT-II treatment significantly inhibited the cell migration. Furthermore, the cell cycle
arrest at G0/G1 phase in AT-II treated cells was presented in the flow cytometry data. Consistently, real-time PCR and
western blotting revealed a remarkable decrease of the CCNA and CCNB expression upon AT-II treatment. Moreover, the
phosphorylation of both extracellular signal-regulated kinase (ERK) and p38 mitogen-activated protein kinase (MAPK)
was triggered by AT-II. Collectively, these results suggested that MAPK signaling was involved in AT-II induced cell cycle
arrest, contributing to the inhibition of cell viability and migration of GBM cells.
Download PDF
33 Downloads 296 Views
| a |
Department of Stem Cells and Regenerative Medicine, Key Laboratory of Cell Biology, National Health Commission
of China, China Medical University, Shenyang 110122 China |
| b |
Key Laboratory of Medical Cell Biology, Ministry of Education of China, China Medical University,
Shenyang 110122 China |
| c |
Department of Food and Drug, Liaoning Agricultural Technical College, Yingkou 115009 China |
* Corresponding author, E-mail: zhangdianbao@gmail.com
Received 13 Aug 2022, Accepted 26 Jul 2023
|
